Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00160693 · ClinicalTrials.gov registry record · Phase 3
Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 402
- Enrollment target
NCT00160693 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 402 participants.
The verdict
NCT00160693, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 402 participants
- Enrollment target
Study Summary
The primary purpose of this study is to obtain long-term safety data with CZP in patients with Rheumatoid Arthritis (RA). Additional objectives are to assess the dose and type of Arthritis medication(s) utilized by patients, and to assess the long-term impact of CZP on physical function. Treatment will continue up to approval of a marketing application for this product.
Interventions
- BIOLOGICAL Certolizumab Pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 402 participants |
| Start Date | 2003-03 |
| Est. Completion | 2011-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00160693
The ClinicalTrials.gov registry entry for NCT00160693 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 402 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Certolizumab Pegol is the first listed.
NCT00160693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00160693 about?
NCT00160693 is a clinical study titled "Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis". The primary purpose of this study is to obtain long-term safety data with CZP in patients with Rheumatoid Arthritis (RA). Additional objectives are to assess the dose and type of Arthritis medication(s) utilized by patients, and to assess the long-term impact of CZP on physical function. Treatment w...
What is the current status of trial NCT00160693?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 402 participants. The study started on 2003-03. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00160693?
The interventions under investigation include: Certolizumab Pegol (BIOLOGICAL).
Who is sponsoring clinical trial NCT00160693?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.